


Intracranial Gliomas Part III: Innovative Treatment Modalities: Progress in Precision Medicine, Targeted Therapies, Immunotherapy, and Beyond



Intracranial Gliomas Part III - Innovative Treatment Modalities (Progress in Neurological Surgery Book 32)

by Christian Seiler

★★★★★ 5 out of 5

Language : English
File size : 5341 KB
Text-to-Speech : Enabled
Screen Reader : Supported
Enhanced typesetting : Enabled
Print length : 222 pages



Precision Medicine in Intracranial Gliomas

Precision medicine, also known as personalized medicine, has revolutionized the treatment of intracranial gliomas. This approach tailors treatment strategies to the unique molecular profile of each patient's tumor.

Genomic analysis, including next-generation sequencing (NGS), plays a crucial role in precision medicine. NGS can identify genetic alterations, such as mutations, copy number variations, and gene fusions, which can guide treatment decisions.

Molecular profiling can predict tumor behavior, response to specific therapies, and prognosis. For example, the presence of IDH1/2 mutations is associated with a more favorable prognosis and sensitivity to certain targeted therapies.

Targeted Therapies for Intracranial Gliomas

Targeted therapies are designed to inhibit specific molecular targets within tumor cells. These therapies have improved outcomes for patients with intracranial gliomas, particularly those with specific genetic alterations.

Examples of targeted therapies include:

- Bevacizumab: An anti-VEGF antibody that inhibits angiogenesis
- Crizotinib: A tyrosine kinase inhibitor that targets ALK mutations
- Vemurafenib: A BRAF inhibitor that targets BRAF V600E mutations
- Everolimus: An mTOR inhibitor that targets the PI3K/AKT/mTOR pathway

Immunotherapy for Intracranial Gliomas

Immunotherapy harnesses the body's immune system to fight cancer. This approach has shown promise in the treatment of intracranial gliomas, particularly in combination with other therapies.

Types of immunotherapy used in intracranial gliomas include:

- Immune checkpoint inhibitors: These drugs block immune checkpoints, which allows immune cells to recognize and attack tumor cells

- CAR T-cell therapy: This therapy involves genetically engineering a patient's T cells to recognize and destroy tumor cells
- Oncolytic viruses: These viruses are engineered to selectively infect and kill tumor cells

Beyond Precision Medicine, Targeted Therapies, and Immunotherapy

In addition to precision medicine, targeted therapies, and immunotherapy, other innovative treatment modalities are being explored for intracranial gliomas.

These include:

- Nanotechnology: Nanoparticles can deliver drugs directly to tumor cells, improving drug delivery and efficacy
- Stem cell therapy: Stem cells can be differentiated into neural cells to replace damaged brain tissue
- Gene therapy: This approach involves introducing genetic material into tumor cells to alter their behavior or sensitivity to treatment


The landscape of treatment for intracranial gliomas is constantly evolving. Innovative treatment modalities, including precision medicine, targeted therapies, immunotherapy, and beyond, are improving outcomes for patients.

Further research is needed to refine these therapies, overcome challenges such as drug resistance, and develop new strategies to improve the overall prognosis for patients with intracranial gliomas.

References

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* 2016;131(6):803-820.
2. Stupp R, Taillibert S, Kanner AA, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone in patients with glioblastoma: a randomized clinical trial. *JAMA.* 2017;318(23):2306-2316.
3. Reardon DA, Brandes AA, Omuro A, et al. Bevacizumab plus irinotecan in recurrent glioblastoma: a randomized, placebo-controlled trial. *Lancet.* 2009;374(9700):1817-1827.
4. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of response of glioblastoma to EGFR kinase inhibitors. *N Engl J Med.* 2005;353(18):1953-1965.
5. Wen PY, Kesari S, Chang SM, et al. Everolimus for the treatment of recurrent subependymal giant cell astrocytomas in tuberous sclerosis complex. *Neuro Oncol.* 2012;14(3):417-422.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med.* 2012;366(26):2443-2454.
7. Besnier C, Broggin Ten Kortenaar N, John LB, et al. CAR T cell therapy for glioblastoma: current challenges and future prospects. *Neuro Oncol.* 2020;22(10):1481-1494.
8. Kheradmand F, Hananya I, Bodmer A, et al. Oncolytic viruses for glioblastoma therapy: current and upcoming approaches. *Neuro Oncol.* 2019;21(8):1085-1097.

9. Zhang Y, Zhang Z, Wang X, et al. Nanocarriers for drug delivery to brain tumors: current progress and future opportunities. *Theranostics*. 2020;10(11):4906-4928.
10. Polivka CA, Patel SP, Nooranipour M, et al. Stem cell therapy for glioblastoma: progress, challenges, and outlook. *Neurosurgery*. 2014;75(4):503-519.
11. Jiang H, Reichert JM. Gene therapy for glioblastoma: past, present, and future. *CNS Oncol*. 2017;6(6):241-250.




Intracranial Gliomas Part III - Innovative Treatment Modalities (Progress in Neurological Surgery Book 32)

by Christian Seiler

★★★★★ 5 out of 5


Language : English
File size : 5341 KB
Text-to-Speech : Enabled
Screen Reader : Supported
Enhanced typesetting : Enabled
Print length : 222 pages





Supercharge Your Child's KS1 Maths Skills with the Ultimate SAT Buster (Comprehensive Guide for Parents)

As a parent, you want to provide your child with the best possible education. When it comes to mathematics, the Key Stage 1 (KS1) SATs (Standard Attainment Tests)...



Santa in Montana: Calder 11 - A Magical Destination for the Holidays

Nestled amidst the picturesque mountains of Montana, Calder 11 is a winter wonderland that transforms into a magical Christmas destination. As you...